Rabies immune globulin (human) is under clinical development by Zydus Lifesciences and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Rabies immune globulin (human)’s likelihood of approval (LoA) and phase transition for Rabies took place on 28 May 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Rabies immune globulin (human) Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Rabies immune globulin (human) overview

Rabies immune globulin (human) (Twinrab), is a cell cultured derived sterile solution containing a large quantity of rabies antibodies. It is formulated as solution for intramuscular route of administration. Twinrab is indicated in combination with rabies vaccine for rabies post-exposure prophylaxis.

Rabimabs is under development for the treatment of rabies virus infections. It is administered intramuscular and intradermal routes. The drug candidate is a combination of two monoclonal antibodies which comprises murine IgG1 monoclonal antibody and murine IgG2b monoclonal antibody (M777-16-3 and MAb 62-71-3). It acts by targeting G-protein (glycoprotein) of the rabies virus envelope. It was also under development for the treatment of cancer.

Zydus Lifesciences overview

Zydus Lifesciences formerly Cadila Healthcare Ltd is an integrated global healthcare provider. It discovers, develops, manufactures and commercializes various healthcare products. The company’s product portfolio includes active pharmaceutical ingredients (APIs), formulations, wellness and animal health products. Zydus Lifesciences products find application in the treatment of diseases in the therapeutic areas of gastrointestinal, cardiovascular, respiratory, pain management, cancer, inflammation, neurology, and women’s health, among others. It conducts research to develop biologics, biosimilars, vaccines and new chemical entities. The company has manufacturing facilities in Gujarat, Goa, Maharashtra, Sikkim and Himachal Pradeshin India; Brazil and the US. It has presence in the US, Europe, South Africa, Japan, Brazil, and other emerging markets. Zydus Lifesciences is headquartered in Ahmedabad, Gujarat, India.

Quick View Rabies immune globulin (human) LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Rabies immune globulin (human)
Administration Pathway
  • Intradermal
  • Intramuscular
Therapeutic Areas
  • Infectious Disease
  • Oncology
Key Developers
Highest Development Stage
  • Marketed


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.